{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:31:49Z","timestamp":1794227509437,"version":"4.9.0"},"reference-count":50,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Cancer therapy containing anthracyclines is associated with cancer-treatment-related cardiac dysfunction and heart failure (HF). Conventional cardioprotective medications can be frequently complicated by their blood-pressure-lowering effect. Recently, elevated resting heart rate was shown to independently predict mortality in patients with cancer. As a heart rate-lowering drug without affecting blood pressure, ivabradine could present an alternative management of anthracyclines-induced cardiotoxicity. Materials and Methods: This study aimed to investigate the probable protective effects of ivabradine in cancer patients with elevated heart rate (&gt;75 beats per minute) undergoing anthracycline chemotherapy. Patients referred by oncologists for baseline cardiovascular risk stratification before anthracycline chemotherapy who met the inclusion criteria and had no exclusion criteria were randomly assigned to one of two strategies: ivabradine 5 mg twice a day (intervention group) or controls. Electrocardiogram, transthoracic echocardiogram with global longitudinal strain (GLS), troponin I (Tn I), and N-terminal natriuretic pro-peptide (NT-proBNP) were performed at baseline, after two and four cycles of chemotherapy and at six months of follow-up. The primary endpoint was the prevention of a &gt;15% reduction in GLS. Secondary endpoints were effects of ivabradine on Tn I, NT-proBNP, left ventricular (LV) systolic and diastolic dysfunction, right ventricle dysfunction, and myocardial work indices. Results: A total of 48 patients were enrolled in the study; 21 were randomly assigned to the ivabradine group and 27 to the control group. Reduced GLS was detected 2.9 times less often in patients receiving ivabradine than in the control group, but this change was non-significant (OR [95% CI] = 2.9 [0.544, 16.274], p = 0.208). The incidence of troponin I elevation was four times higher in the control group (OR [95% CI] = 4.0 [1.136, 14.085], p = 0.031). There was no significant change in NT-proBNP between groups, but the increase in NT-proBNP was almost 12% higher in the control group (OR [95% CI] = 1.117 [0.347, 3.594], p = 0.853). LV diastolic dysfunction was found 2.7 times more frequently in the controls (OR [95% CI] = 2.71 [0.49, 15.10], p = 0.254). Patients in the ivabradine group were less likely to be diagnosed with mild asymptomatic CTRCD during the study (p = 0.045). No differences in right ventricle function were noted. A significant difference was found between the groups in global constructive work and global work index at six months in favour of the ivabradine group (p = 0.014 and p = 0.025). Ivabradine had no adverse effects on intracardiac conduction, ventricular repolarization, or blood pressure. However, visual side effects (phosphenes) were reported in 14.3% of patients. Conclusions: Ivabradine is a safe, well-tolerated drug that has shown possible cardioprotective properties reducing the incidence of mild asymptomatic cancer-therapy-induced cardiac dysfunction, characterised by a new rise in troponin concentrations and diminished myocardial performance in anthracycline-treated women with breast cancer and increased heart rate. However, more extensive multicentre trials are needed to provide more robust evidence.<\/jats:p>","DOI":"10.3390\/medicina59122140","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T06:56:00Z","timestamp":1702277760000},"page":"2140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial"],"prefix":"10.3390","volume":"59","author":[{"given":"Egl\u0117","family":"\u010ciburien\u0117","sequence":"first","affiliation":[{"name":"Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"},{"name":"Center of Cardiology and Angiology, Vilnius University Hospital \u201cSantaros Clinics\u201d, 08661 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigita","family":"Aidietien\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"},{"name":"Center of Cardiology and Angiology, Vilnius University Hospital \u201cSantaros Clinics\u201d, 08661 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"\u0160\u010derbickait\u0117","sequence":"additional","affiliation":[{"name":"Center of Cardiology and Angiology, Vilnius University Hospital \u201cSantaros Clinics\u201d, 08661 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0372-6996","authenticated-orcid":false,"given":"Egl\u0117","family":"Sadauskien\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"},{"name":"Center of Cardiology and Angiology, Vilnius University Hospital \u201cSantaros Clinics\u201d, 08661 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Sudavi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"},{"name":"Center of Cardiology and Angiology, Vilnius University Hospital \u201cSantaros Clinics\u201d, 08661 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5089-9136","authenticated-orcid":false,"given":"Edita","family":"Baltru\u0161kevi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birut\u0117","family":"Brasi\u016bnien\u0117","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania"},{"name":"Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Drobnien\u0117","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Institute, 08406 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"\u010celutkien\u0117","sequence":"additional","affiliation":[{"name":"Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania"},{"name":"Center of Cardiology and Angiology, Vilnius University Hospital \u201cSantaros Clinics\u201d, 08661 Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","article-title":"Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention","volume":"104","author":"Henriksen","year":"2017","journal-title":"Heart"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.2459\/JCM.0000000000000378","article-title":"Pathophysiology of anthracycline cardiotoxicity","volume":"17","author":"Mele","year":"2016","journal-title":"J. Cardiovasc. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early Detection of Anthracycline Cardiotoxicity and Improvement with Heart Failure Therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial","volume":"134","author":"Beheshti","year":"2016","journal-title":"Cardiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","article-title":"Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up","volume":"85","author":"Georgakopoulos","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ejhf.670","article-title":"Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: Results of a prospective cardiovascular long-term study","volume":"18","author":"Anker","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/VHRM.S90383","article-title":"Advances in the management of heart failure: The role of ivabradine","volume":"12","author":"Werdan","year":"2016","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/ejhf.689","article-title":"Heart rate: From heart failure to chronic diseases and cancer. Is there a role for supportive care by heart rate reduction?","volume":"19","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1753944720934937","DOI":"10.1177\/1753944720934937","article-title":"Ivabradine and endothelium: An update","volume":"14","author":"Dallapellegrina","year":"2020","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/FJC.0000000000000586","article-title":"Possible Ameliorative Effect of Ivabradine on the Autonomic and Left Ventricular Dysfunction Induced by Doxorubicin in Male Rats","volume":"72","author":"Sharabi","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_14","unstructured":"Ibrahim, A.N., and Mousa, A.M. (2018, September 18). Effects of Ivabradine on Cardiotoxicity Induced by Doxorubicin Treatment in Rats. Available online: www.medicaljournalofcairouniversity.net."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.20996\/1819-6446-2017-13-2-184-190","article-title":"Possibilities of ivabradine, a selective inhibitor of ion f-channels of sinus node, in prevention of anthracycline cardiotoxicity in patients with breast cancer","volume":"13","author":"Vasyuk","year":"2017","journal-title":"Ration. Pharmacother. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.2017","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: A position statement on behalf of the H eart F ailure A ssociation (HFA), the E uropean A ssociation of C ardiovascular I maging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ferreira, V.V., Mano, T.B., Cardoso, I., Cruz, M.C., Branco, L.M., Almeida-Morais, L., Tim\u00f3teo, A., Galrinho, A., Castelo, A., and Br\u00e1s, P.G. (2022). Myocardial Work Brings New Insights into Left Ventricular Remodelling in Cardio-Oncology Patients. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19052826"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"77","author":"Thavendiranathan","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial","volume":"71","author":"Avila","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Chow, S.C., Shao, J., Wang, H., and Lokhnygina, Y. (2017). Sample Size Calculations in Clinical Research, CRC Press. [3rd ed.].","DOI":"10.1201\/9781315183084"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the. European Society of Cardiology (ESC) With the special contributio","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/FJC.0000000000000597","article-title":"Ivabradine\u2019s Pleiotropic Profile: Can it protect against doxorubicin-induced heart failure?","volume":"72","author":"Verrier","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s10787-022-01082-z","article-title":"The role of ivabradine in doxorubicin-induced cardiotoxicity: Exploring of underlying argument","volume":"30","author":"Issa","year":"2022","journal-title":"Inflammopharmacology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e04133","DOI":"10.1002\/ccr3.4133","article-title":"Impact of ivabradine in decompensated heart failure due to cancer therapy-related cardiac dysfunction","volume":"9","author":"Nakano","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"766","DOI":"10.33963\/KP.a2023.0108","article-title":"Anthracycline-induced microcirculation disorders: AIM PILOT Study","volume":"81","author":"Klotzka","year":"2023","journal-title":"Kardiologia Polska"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies: The OVERCOME trial (prevention of left ventricular dysfunction with enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e006513","DOI":"10.1161\/JAHA.117.006513","article-title":"Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study","volume":"6","author":"Gulati","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity a Systematic Review and Meta-analysis","volume":"4","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_34","first-page":"140","article-title":"Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and\/or Trastuzumab Treatment","volume":"110","author":"Gripp","year":"2018","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2015.02.004","article-title":"Strain echocardiography combined with pharmacological stress test for early detection of anthracycline induced cardiomyopathy","volume":"73","author":"Burdick","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_36","first-page":"392","article-title":"Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity","volume":"18","author":"Charbonnel","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/ehjci\/jex033","article-title":"2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: A balance with feasibility","volume":"18","author":"Santoro","year":"2017","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy: A Systematic Review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Negishi, T., Thavendiranathan, P., Penicka, M., Lemieux, J., Aakhus, S., Miyazaki, S., Shirazi, M., Galderisi, M., Cho, G.Y., and Popescu, B.A. (2023, March 17). Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 1 Year Results of the SUCCOUR Trial. Available online: https:\/\/academic.oup.com\/eurheartj\/article\/41\/Supplement_2\/ehaa946.3282\/6004273.","DOI":"10.1093\/ehjci\/ehaa946.3282"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry","volume":"41","author":"Lyon","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 3 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol In patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricu-lar function","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.clon.2019.11.008","article-title":"Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy","volume":"32","author":"Tzolos","year":"2020","journal-title":"Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12282-017-0778-8","article-title":"High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients","volume":"24","author":"Kitayama","year":"2017","journal-title":"Breast Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jcmg.2019.07.018","article-title":"Comprehensive Assessment of Changes in Left Ventricular Diastolic Function with Contemporary Breast Cancer Therapy","volume":"13","author":"Upshaw","year":"2020","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jcmg.2018.01.015","article-title":"Abnormalities in 3-Dimensional Left Ventricular Mechanics with Anthracycline Chemotherapy Are Associated with Systolic and Diastolic Dysfunction","volume":"11","author":"Zhang","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"\u010ciburien\u0117, E., Aidietien\u0117, S., \u0160\u010derbickait\u0117, G., Brasi\u016bnien\u0117, B., Drobnien\u0117, M., Baltru\u0161kevi\u010dien\u0117, E., \u017dvirblis, T., and \u010celutkien\u0117, J. (2022). Development of a Cardio-Oncology Service in Lithuania: Prediction, Prevention, Monitoring and Treatment of Cancer Treatment-Induced Cardiotoxicity. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9050134"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","article-title":"Prevention of anthracycline-induced cardiotoxicity: A systematic review and meta-analysis","volume":"16","author":"Caspani","year":"2020","journal-title":"Intern. Emerg. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of High-Dose Chemotherapy\u2013Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jcmg.2022.03.021","article-title":"Myocardial Work in Cardio-Oncology","volume":"15","author":"Argulian","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100818","DOI":"10.1016\/j.cpcardiol.2021.100818","article-title":"Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques","volume":"46","author":"Manno","year":"2021","journal-title":"Curr. Probl. Cardiol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/12\/2140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:59Z","timestamp":1760132159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/12\/2140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["medicina59122140"],"URL":"https:\/\/doi.org\/10.3390\/medicina59122140","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]}}}